300497 Stock Overview
Engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Jiangxi Fushine Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.06 |
| 52 Week High | CN¥13.68 |
| 52 Week Low | CN¥5.62 |
| Beta | 0.28 |
| 1 Month Change | -20.98% |
| 3 Month Change | -16.82% |
| 1 Year Change | -8.51% |
| 3 Year Change | -53.94% |
| 5 Year Change | -33.56% |
| Change since IPO | 110.26% |
Recent News & Updates
Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Dec 23
Does Jiangxi Fushine Pharmaceutical (SZSE:300497) Have A Healthy Balance Sheet?
Dec 02There's Reason For Concern Over Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Massive 28% Price Jump
Oct 04Recent updates
Jiangxi Fushine Pharmaceutical Co., Ltd. (SZSE:300497) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Dec 23Does Jiangxi Fushine Pharmaceutical (SZSE:300497) Have A Healthy Balance Sheet?
Dec 02There's Reason For Concern Over Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Massive 28% Price Jump
Oct 04Is Jiangxi Fushine Pharmaceutical (SZSE:300497) A Risky Investment?
Jun 12What Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) 26% Share Price Gain Is Not Telling You
May 06Jiangxi Fushine Pharmaceutical Co., Ltd.'s (SZSE:300497) Business And Shares Still Trailing The Industry
Feb 27Shareholder Returns
| 300497 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.4% | -3.0% | -4.0% |
| 1Y | -8.5% | -6.5% | 6.4% |
Return vs Industry: 300497 underperformed the CN Pharmaceuticals industry which returned -6.5% over the past year.
Return vs Market: 300497 underperformed the CN Market which returned 6.4% over the past year.
Price Volatility
| 300497 volatility | |
|---|---|
| 300497 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.1% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 300497 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300497's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,963 | Jian Hua Bao | www.fushine.cn |
Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers penicillin, carbapenem, and other products, as well as intermediates of antiviral drugs. It also provides contract research, development, and manufacturing services, as well as engages in lithium battery electrolyte additives.
Jiangxi Fushine Pharmaceutical Co., Ltd. Fundamentals Summary
| 300497 fundamental statistics | |
|---|---|
| Market cap | CN¥4.46b |
| Earnings (TTM) | -CN¥181.24m |
| Revenue (TTM) | CN¥1.30b |
3.3x
P/S Ratio-24.0x
P/E RatioIs 300497 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300497 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.30b |
| Cost of Revenue | CN¥1.21b |
| Gross Profit | CN¥90.46m |
| Other Expenses | CN¥271.70m |
| Earnings | -CN¥181.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 28, 2025
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 6.96% |
| Net Profit Margin | -13.94% |
| Debt/Equity Ratio | 67.8% |
How did 300497 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 09:25 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jiangxi Fushine Pharmaceutical Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Wen Shen | Avic Securities Co., Ltd |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Andy Liu | China Stock Investment Research Co. Ltd. (GZ500..com) |